Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results